First EFIC® Symposium Societal Impact of Pain - SIP

62
Paul Kind
Prof. Paul Kind
Centre for Health Economics
Alcuin College
University of York
York YO10 5DD
UK
Measuring the value of pain in economic
evaluation
National regulatory agencies increasingly rely
on evidence of cost-effectiveness. At the heart
of this economic analysis is the fundamental
issue as to whether the additional benefits of a
new therapy outweigh the additional costs of
providing it. Economists take a strict view on
two key questions – HOW such benefits should
be measured and WHO should be asked to
make those measurements.
This workshop will briefly summarise the
processes involved and identify the strengths
and weaknesses of the economist’s analytic
approach.
Biosketch
Paul Kind has a background in economics,
psychology and computer science. His
research career dates back more than 30
years and has centred primarily around the
development and application of health status
measures for use in clinical and economic
evaluation. Paul combines his academic
research with consultancy in the field of healthrelated
quality of life, both within the NHS and
the international pharmaceutical industry. He
is a Professor of Health Economics in the
Centre for Health Economics at the University
of York. He has held similar visiting positions in
the Department of Pharmacy, University of
Uppsala, Sweden, McGill University, Montreal
and the University of Wisconsin, Madison. He
has been a Faculty Member of the Netherlands
Institute for Health Sciences Erasmus
University, Rotterdam and an Honorary Fellow
of the National Centre for Quality of Life
Research, St. Petersburg and has served as
an elected member of the Board of the
International Society for Quality of Life
Research (ISOQOL) and as SIG leader for the
International Society for Pharmacoeconomics
and Outcomes Research (ISPOR). Paul is
currently an elected member of the Board of
ISPOR. A Founder Member and past-President
of the EuroQoL Group, he Chairs its Scientific
Executive Committee.